Panavance Therapeutics, Inc.
Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company focused on developing a novel oncology drug, misetionamide, to improve outcomes for cancer patients. Founded in 2021 in Delaware, USA, the company aims to disrupt cancer's energy metabolism with its unique mechanism of action, targeting multiple cancer types and stages.
Industries
Nr. of Employees
small (1-50)
Panavance Therapeutics, Inc.
Products
Clinical-stage small-molecule oncology asset (energy metabolism inhibitor)
A clinical-stage small-molecule therapeutic with a patent-pending mechanism that inhibits oncogenic transcription factors to disrupt tumor cell energy metabolism; advanced into a Phase I multicenter dose-escalation study with planned indication trials.
Clinical-stage small-molecule oncology asset (energy metabolism inhibitor)
A clinical-stage small-molecule therapeutic with a patent-pending mechanism that inhibits oncogenic transcription factors to disrupt tumor cell energy metabolism; advanced into a Phase I multicenter dose-escalation study with planned indication trials.
Services
Clinical development and trial execution for oncology small molecules
Design and execution of multicenter clinical trials for oncology small-molecule therapeutics, including Phase I dose-escalation studies.
Clinical development and trial execution for oncology small molecules
Design and execution of multicenter clinical trials for oncology small-molecule therapeutics, including Phase I dose-escalation studies.
Expertise Areas
- Clinical trial management (Phase I dose-escalation, multicenter)
- Mechanism-of-action driven oncology R&D
- Translational oncology
- Small-molecule therapeutic development
Key Technologies
- Small-molecule drug development
- Mechanism-of-action elucidation (transcription factor inhibition)
- Cancer cell energy metabolism targeting
- Preclinical in vivo tumor models